Effects of adenosine A(3) receptor agonist on bone marrow granulocytic system in 5-fluorouracil-treated mice
Language English Country Netherlands Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
16643889
DOI
10.1016/j.ejphar.2006.03.042
PII: S0014-2999(06)00290-1
Knihovny.cz E-resources
- MeSH
- Adenosine administration & dosage analogs & derivatives pharmacology MeSH
- Adenosine A3 Receptor Agonists * MeSH
- Bone Marrow Cells cytology drug effects MeSH
- Time Factors MeSH
- Fluorouracil administration & dosage pharmacology MeSH
- Granulocytes cytology drug effects MeSH
- Immunosuppressive Agents administration & dosage pharmacology MeSH
- Injections, Intraperitoneal MeSH
- Mice MeSH
- Cell Proliferation drug effects MeSH
- Animals MeSH
- Check Tag
- Male MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Adenosine MeSH
- Adenosine A3 Receptor Agonists * MeSH
- Fluorouracil MeSH
- Immunosuppressive Agents MeSH
- N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine MeSH Browser
The purpose of the experiments reported was to investigate effects of N(6)-(3-iodobenzyl)adenosine-5'-N-methyluronamide (IB-MECA), a selective adenosine A(3) receptor agonist, on the granulocytic system in femoral marrow of mice depleted by the cytotoxic drug 5-fluorouracil. In the phase of the highest cell depletion IB-MECA was injected i.p. at single doses of 200 nmol/kg given either once or twice daily in 2- and 4-day regimens starting on day 1 after 5-fluorouracil administration; the effects were evaluated on days 3 and 5, respectively. The general effect of IB-MECA in all these experiments was an enhancement of the counts of morphologically recognizable proliferative granulocytic cells, interpreted as evidence of the differentiation of committed progenitor cells. A more expressive effect was observed after IB-MECA injected twice daily. It was found that the induction of the strong differentiation pressures by IB-MECA given twice daily shortly after 5-fluorouracil treatment can be counterproductive due to the preponderance of differentiaton processes over the proliferation control. In additional experiments, it has been shown that the use of the 2-day administration of IB-MECA given twice daily in the recovery phase, i.e., on days 5 and 6 after 5-fluorouracil administration, does not induce stimulatory effects. Thus, the dosing and timing of IB-MECA treatment determines its effectivity in stimulating granulopoiesis under conditions of myelosuppression.
References provided by Crossref.org
The role of adenosine receptor agonists in regulation of hematopoiesis